← Back to Search

Janus Kinase Inhibitor

Abrocitinib for Sarcoidosis

Phase 2
Recruiting
Led By William Damsky, M.D.
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of moderate to severe cutaneous sarcoidosis (CSAMI of 10 or greater) with supportive skin biopsy in which other causes of granulomas (infectious, foreign body) have been ruled out
Cutaneous Sarcoidosis Activity and Morphology (CSAMI) activity score greater than or equal to 10 (patients with a CSAMI greater than or equal to 10 have active cutaneous sarcoidosis involving several distinct cutaneous sites, have moderate to severe disease and would otherwise be considered candidates for systemic therapy), or
Must not have
Age <18 years old
Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new pill called abrocitinib for patients with moderate to severe skin sarcoidosis. The pill aims to reduce inflammation by targeting a specific protein in the immune system. Researchers hope this will improve skin lesions better than current treatments.

Who is the study for?
Adults with moderate to severe cutaneous sarcoidosis, confirmed by skin biopsy, can join this trial. They must have been on stable medication doses for 3 months if using other treatments and agree to not change these during the study. Women who can get pregnant need a negative pregnancy test and must use birth control. People with certain infections, liver or kidney issues, clotting disorders, cancer (except certain skin cancers), or taking strong drug inhibitors are excluded.
What is being tested?
The trial is testing abrocitinib 200 mg daily as an oral treatment for patients with moderate to severe cutaneous sarcoidosis. The goal is to see how effective it is in reducing symptoms of the disease when taken once every day.
What are the potential side effects?
Potential side effects of abrocitinib may include increased risk of infections due to immune system suppression, changes in blood tests like platelets or neutrophils which could indicate blood disorders, possible liver function changes and potential interactions with other medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with severe skin sarcoidosis, confirmed by a biopsy.
Select...
My skin condition is severe and affects many areas, needing systemic treatment.
Select...
My skin condition affects my nose or vision.
Select...
I am willing to undergo skin biopsies, blood tests, and full body photos for the study.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.
Select...
I have had cancer before, but it was not skin cancer that was successfully treated.
Select...
My skin condition's severity score is 10 or less.
Select...
I have been diagnosed with Rheumatoid Arthritis.
Select...
My liver is not working well (severe impairment).
Select...
My kidneys do not work well.
Select...
I have an untreated stomach ulcer.
Select...
I have a history of blood clots, including in my veins or lungs.
Select...
I am a woman who can have children and will not use birth control while on the medication.
Select...
I am not pregnant or nursing.
Select...
I am not on medications that strongly affect my body's drug processing enzymes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in Cutaneous Sarcoidosis Activity and Morphology Instrument (CASMI) score
Secondary study objectives
Changes in Fatigue Assessment Scale (FAS)
Changes in Patient Reported Outcomes Quality of Life (King's Sarcoidosis Questionnaire)
Changes in Rhinosinustitis Disability Index (RSDI)
+2 more

Side effects data

From 2021 Phase 3 trial • 727 Patients • NCT04345367
19%
Nausea
13%
Headache
13%
Acne
5%
Dermatitis atopic
4%
Blood creatine phosphokinase increased
4%
SARS-CoV-2 test positive
4%
COVID-19
4%
Nasopharyngitis
3%
Fatigue
3%
Folliculitis
3%
Upper respiratory tract infection
3%
Natural killer cell count decreased
3%
Dizziness
3%
Vomiting
3%
Herpes simplex
2%
Oral herpes
2%
Urinary tract infection
2%
Weight increased
2%
Epistaxis
2%
Diarrhoea
2%
Conjunctivitis
2%
Herpes zoster
1%
Arthralgia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Abrocitinib 200 mg QD
Dupilumab 300 mg Q2W

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Abrocitinib 200 mg dailyExperimental Treatment1 Intervention
6 months of treatment with abrocitinib 200 mg daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abrocitinib 200 mg
2022
Completed Phase 3
~930

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Sarcoidosis include immunosuppressive therapies such as glucocorticoids, methotrexate, and TNF inhibitors, which work by reducing inflammation and modulating the immune response. Glucocorticoids suppress the overall immune activity, methotrexate inhibits the metabolism of folic acid affecting immune cell proliferation, and TNF inhibitors block the action of tumor necrosis factor-alpha, a key cytokine in inflammation. JAK inhibitors like Abrocitinib target the Janus kinase pathways, which are involved in the signaling of various cytokines that drive inflammation. These treatments are crucial for Sarcoidosis patients as they help control the excessive immune response that leads to granuloma formation and organ damage.

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,675 Previous Clinical Trials
28,717,172 Total Patients Enrolled
3 Trials studying Sarcoidosis
21 Patients Enrolled for Sarcoidosis
Yale UniversityLead Sponsor
1,930 Previous Clinical Trials
3,033,448 Total Patients Enrolled
4 Trials studying Sarcoidosis
5,040 Patients Enrolled for Sarcoidosis
William Damsky, M.D.Principal InvestigatorYale University
1 Previous Clinical Trials
10 Total Patients Enrolled

Media Library

Abrocitinib (Janus Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05696795 — Phase 2
Sarcoidosis Research Study Groups: Abrocitinib 200 mg daily
Sarcoidosis Clinical Trial 2023: Abrocitinib Highlights & Side Effects. Trial Name: NCT05696795 — Phase 2
Abrocitinib (Janus Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05696795 — Phase 2
~0 spots leftby Dec 2024